PERSPECTA

News from every angle

← Back to headlines

Madrigal Pharmaceuticals Projects 2026 Gross-to-Net, Advances F4c Outcomes

Madrigal Pharmaceuticals anticipates its 2026 gross-to-net revenue to be in the mid-to-high 30s, while also progressing towards an F4c outcomes readout expected in 2027.

6 May, 18:02 — 6 May, 18:02
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed5h ago

Madrigal sees 2026 gross-to-net in the mid- to high 30s while advancing F4c outcomes readout expected in 2027

Read full article →

Related Stories

MV Hondius Hantavirus Case Prompts Global Health Response

14m ago

WHO Rules Out Onboard Hantavirus Infection on Ship

14m ago

Cruise Ship with Hantavirus Patients Heads to Tenerife

19m ago

Stronger Glutes Can Alleviate Knee and Back Pain

27m ago